Background
==========

Gastric cancer (GC) is considered the 4^th^ most prevalent malignancy and the 2^nd^ foremost trigger of cancer deaths globally \[[@b1-medscimonit-24-2259]\]. Accordingly, surgical treatment is the only curative therapeutic option for GC \[[@b2-medscimonit-24-2259],[@b3-medscimonit-24-2259]\]. Even though some advances have been made in its retreatment in the recent past, most patients with GC eventually die from recurrence \[[@b3-medscimonit-24-2259]\]. As such, finding an effective biomarker that can predict the behavior of the tumor is urgently needed in clinical practice.

Peroxiredoxin 1 (Prdx1) is an affiliate of the thiol-dependent peroxiredoxin family of antioxidant enzymes, which regulates the levels of cytokine-induced peroxide. It also facilitates transduction of signal in mammalian cells \[[@b4-medscimonit-24-2259]\]. Prdx1 activity has previously been reported to be involved in several biological processes, such as differentiation of cells, apoptosis, and proliferation \[[@b5-medscimonit-24-2259]\]. Many studies have also proposed that Prdx1 can be decontrolled in different cancer types like prostate cancer \[[@b6-medscimonit-24-2259]\], bladder cancer \[[@b7-medscimonit-24-2259]\], lung cancer \[[@b8-medscimonit-24-2259]\], and liver cancer \[[@b9-medscimonit-24-2259]\].

In the present study, Prdx1 expression was detected and its associations with clinicopathological factors as well as prognosis in GC tissues were examined. Prdx1 was found to be overexpressed in GC tissues at mRNA and protein levels. It was also found to be correlated with a high degree of differentiation and advanced TNM stage. Importantly, Prdx1 overexpression predicted an inferior overall and disease-free survival, and could therefore be a latent self-regulating GC prognostic biomarker. Our study results also suggest that Prdx1 may improve the progression of GC through the mechanism of epithelial-mesenchymal transition (EMT).

Material and Methods
====================

Clinical and tissue samples
---------------------------

Specimens of GC were selected from 189 cases, which were gathered together with the paracarcinomatous tissues, from patients diagnosed at the Anhui Provincial Cancer Hospital (Hefei, China) during the period of 2008 to 2012. From this, comprehensive pathological and clinical data (e.g., age, sex, tumor size, Borrmann type, level of differentiation, histological type, invasion depth, lymph node metastasis, and TNM stage) were acquired from medical records of the patients. The samples were from 134 male and 55 female patients with an average age of 68 years (range: 24--83 years). Tumor stage was then determined as per the 7^th^ edition of the tumor-node-metastasis (TNM) classification of the International Union Against Cancer. None of the patients had undergone radiotherapy or chemotherapy prior to the surgery. Specimens were fixed in formalin, then embedded in paraffin awaiting pathological analysis and diagnosis confirmation. Comprehensive clinical sequel data were obtained from the Anhui Provincial Cancer Hospital GC database. The study was approved by the Human Research Ethics Committee of Anhui Provincial Cancer Hospital, and an informed consent was acquired from every patient.

Immunohistochemistry and scoring
--------------------------------

Immunohistochemistry for Prdx1 and E-cadherin (E-Ca) was carried out on every tumor specimen. The tumor samples were cut into sections (4-μm thick) and placed onto silanized glass slides. Then, two-step immunohistochemical was used to detect expression of proteins. In brief, deparaffinized and hydrated sections were preserved with 0.3% hydrogen peroxide in methanol for 15 min at room temperature to obstruct activities of endogenous peroxidase. Then, they were washed in phosphate-buffered saline (PBS; 3×3 min). Antigen retrieval was performed in citrate buffer (pH 6.0). Following washing in PBS (3×3 min), the sections were stained with an Prdx1 monoclonal antibody (Abcam, Cambridge, MA, United States) and E-Ca monoclonal antibody (Beijing Zhongshan Biotechnology, Beijing, China) for about 2 h at 37°C. Then, they were washed in PBS (3 ×3 min). The sections were incubated using the Universal IgG antibody-HRP polymer for about 15 min at 37°C. Subsequently, they were washed 3 times (PBS; 3×3 min). Ultimately, every section was treated using 50 μl diaminobenzidine (DAB) working solution at room temperature for about 3--10 min before washing in PBS. All the sections were counterstained by hematoxylin.

Each of the sections were scored according to the portion of stained tumor cells and the intensity of staining. The proportion of stained tumor cells was categorized as 0 (≤1%), 1 (2% to 25%), 2 (26% to 50%), 2 (51% to 75%), and 4 (≥76%). The intensity of staining was scored as 0 (no staining), 1 (weak), 2 (moderate), and 3 (strong). The outcome of expression was established by use of the following formula: percentage score × intensity score. A general score of 0--12 was considered as low (score: 0--3) or high (score: 4--12). All the stained portions were assessed by 2 pathologists blinded to the data.

Western blotting analysis
-------------------------

Cells were washed in PBS and lysed in RIPA lysis buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 50 mM EDTA, 1% Triton X-100) at 4°C for 30 min. Then, whole-cell extracts were collected and centrifuged at 12 000 rpm for 15 min at 4°C. Afterwards, the supernatants were removed with a pipette and protein concentration was detected using the Bradford method. Equal amounts of lysate protein were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. After that, the membrane was blocked with 5% BSA and incubated in primary antibodies against E-cadherin, Vimentin, Snail, Prx1, and GAPDH overnight at 4°C. On the next day, the membrane was incubated in a horseradish peroxidase-conjugated secondary antibody and immunoreactive proteins were visualized by an ECL system.

Quantitative real-time PCR
--------------------------

Total RNA was isolated from carcinoma and para-carcinoma tissue treated by TRIzol and DNase I. Total RNA was reverse-transcribed to cDNA by a high-capacity cDNA reverse transcription kit according to the manufacturer's instructions. Snail and Slug mRNA levels were examined by real-time PCR using a SYBR Green quantitative PCR kit (Bio-Rad) and a C1000™ thermal cycler. PCR primer sequences were as follow: human Prdx1, forward 5′-CCACGGAGATCATTGCTTTCA-3′ and reverse 5′-AGGTGTATTGACCCATGCTAGAT-3′. Each sample was tested in triplicate and expression of each target was normalized to that of the human GAPDH gene.

Cell culture and treatment
--------------------------

The human Prx1 gene sequence was ascertained in a human placental cDNA library. The human gastric cancer cell line was cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/mL), and streptomycin (100 lg/mL). The cells were incubated at 37°C and in a humidified environment of 5% CO~2~. We used 20 nM siRNA or pC3.1-myc-hPrx1 plasmid in the transfection with Lipofectamine 2000 according with the manufacturer's protocol. Prx1 siRNA (si-Prx1) oligos were as follow: sense 5′-GCCGAAUUGUGGUGUCUUAUU-3′ and antisense 5′-UAAGACACCACAAUUCGGCUU-3′. Cell morphology was observed using an inverted phase-contrast microscope.

Transwell invasion and metastasis experiments
---------------------------------------------

Cells were cultured in 6-well plates at 37°C with 5% CO~2~ in 1640 medium with 1% penicillin and streptomycin and 10% FBS until the cells had grown to confluence. Then, the monolayer of cells was wounded with pipette tips, washed with PBS to wipe off the deciduous cells, and incubated for 24 h. The degree of cell migration was determined by the images of the wounded area taken by microscopy (Leica DMi8, Solms, Germany).

Transwell inserts (Corning Costar, Cambridge, MA, USA) were coated with Matrigel Basement Membrane Matrix and incubated for 30 min at 37°C. We pipetted 2×10^5^ cells suspended in serum-free 1640 medium into the upper chamber and 500 μl 1640 medium with 10% FBS was added in the bottom chambers. After 24-h incubation, the Transwell plates were fixed by paraformaldehyde for 5 min and stained with crystal violet for 1 min. After that, the cells in the upper chamber were eliminated using a cotton swab and invasive cells were photographed using a digital camera (OLYMPUS BX43, Tokyo, Japan).

Statistical analysis
--------------------

All the statistical evaluations were carried out using the statistical package SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). We used the chi-square test and Spearman correlation test in analyzing the results of immunohistochemistry. Then, the Kaplan-Meier technique and log-rank test were used in survival analysis. The Cox regression model was used in determining the value of independent prognostic factors. All *P* values were 2-sided and *P*\<0.05 was regarded as statistically significant.

Results
=======

Prdx1 and E-Ca expression in cancerous gastric tissues
------------------------------------------------------

In further evaluating the expression level of Prdx1 and E-Ca in GC tissues, we detected the protein expression of Prdx1 and E-Ca in 189 GC tissue samples compared with matched adjacent non-cancerous gastric tissue samples. High and low expressions of Prdx1 and E-Ca in GC tissues are displayed in [Figure 1](#f1-medscimonit-24-2259){ref-type="fig"}, showing that Prdx1 staining was greatest in the tumor cells' cytoplasm. Consistent with the above observation, the mRNA and protein levels of Prdx1 in the GC tissues were higher than in the corresponding peri-tumor tissues ([Figures 2](#f2-medscimonit-24-2259){ref-type="fig"}, [3](#f3-medscimonit-24-2259){ref-type="fig"}). High expression of Prdx1 was found in most of the GC tissue samples (127/189) but was found in fewer of the non-cancerous gastric tissue samples (43/189). Accordingly, the Prdx1 expression in GC was substantially higher as compared with that of the non-cancerous tissue samples (P\<0.001). There was also an observable significant correlation between the expression of Prdx1 and E-Ca, as shown in [Table 1](#t1-medscimonit-24-2259){ref-type="table"}. High expression of Prdx1 was associated with low expression of E-Ca (r=−0.154, P=0.035) in GC tissues.

Association of Prdx1 and E-Ca expression with clinicopathological parameters
----------------------------------------------------------------------------

In examining the functions of Prdx1 and E-Ca in GC tissues, we assessed the relationship of their expressions and the clinicopathological parameters of the GC patients. The expression of Prdx1 was significantly linked to the level of differentiation (P=0.006), invasion depth (P=0.001), lymph node metastasis (P=0.029), and TNM stage (P\<0.001), as illustrated in [Table 2](#t2-medscimonit-24-2259){ref-type="table"}. In addition, E-Ca expression was higher in early-stage tumors (P=0.037). Statistical analysis showed that expression of E-Ca was correlated with the level of differentiation (P=0.033) and the depth of invasion (P\<0.001). The detailed results are shown in [Table 2](#t2-medscimonit-24-2259){ref-type="table"}.

Correlation of Prdx1 and E-Ca expression with prognosis
-------------------------------------------------------

The association of Prdx1 expression with prognosis was further analyzed by use of Kaplan-Meier survival curve and log-rank test. The Kaplan-Meier curves were plotted in comparing the OS and the DFS according to the Prdx1 expression patterns. We found that patients who had high expression of Prdx1 had worse OS (38.207 months, P\<0.001) and DFS (35.519 months, P\<0.001) than in those who had low Prdx1 expression (58.502 months, P\<0.001; 56.937 months, P\<0.001), as shown in [Tables 3](#t3-medscimonit-24-2259){ref-type="table"}, [4](#t4-medscimonit-24-2259){ref-type="table"} and [Figure 4](#f4-medscimonit-24-2259){ref-type="fig"}. In contrast, the low expression of E-Ca was significantly associated with poor OS (P\<0.001) and poor DFS (P\<0.001) ([Figure 5](#f5-medscimonit-24-2259){ref-type="fig"}). In the multivariate analysis, depth of invasion (P=0.004 for OS, P=0.006 for DFS), lymph node metastasis (P=0.005 for OS, P=0.006 for DFS), Prdx1 expression (P=0.001 for OS, P=0.001 for DFS), and E-Ca expression (P=0.021 for OS, P=0.013 for DFS) were the independent factors ([Tables 5](#t5-medscimonit-24-2259){ref-type="table"}, [6](#t6-medscimonit-24-2259){ref-type="table"}).

Prdx1 promotes GC cell invasion and metastasis through EMT mechanism
--------------------------------------------------------------------

To further explore the role of Prdx1 in GC, the GC cell lines (SGC-7901 and MGC-803) were used. As shown in [Figure 6](#f6-medscimonit-24-2259){ref-type="fig"}, inhibition of Prdx1 significantly attenuated the invasion and metastasis ability of SGC-7901 and MGC-803 cell lines. Additionally, we also detected the EMT-related markers (E-Ca, Snail, and Vimentin) in the GC cells after inducing Prdx1 deficiency. The Western blotting results revealed that the protein levels of these EMT-related markers were significantly downregulated at 48 h after transfection with si-Prdx1 in the GC cells in comparison with the blank control cells ([Figure 7](#f7-medscimonit-24-2259){ref-type="fig"}).

Discussion
==========

It is well known that gastric cancer is among the foremost causes of cancer-related deaths globally \[[@b1-medscimonit-24-2259]\]. In assessing prognosis for GC patients, the TNM staging system and the Lauren classification system have been extensively used in clinical practice \[[@b10-medscimonit-24-2259]\]. Nonetheless, these predictive models are not helpful indicators of prognosis in GC patients. As such, identifying molecules with tumorigenic properties has contributed to the understanding of tumor progression in gastric cancer.

Recent evidence from several publications show that Prdx1 expression patterns are associated with human cancers \[[@b11-medscimonit-24-2259]\]. Prdx1 facilitates the tumor-suppressive role of PTEN through binding PTEN and shielding its lipid phosphatase activity from H~2~O~2~-induced inactivation \[[@b12-medscimonit-24-2259]\]. Additionally, Prdx1 hypermethylation and abridged expressions have been noted in oligodendroglial tumors. Knockdown of Prdx1 substantially amplifies apoptosis and reduces viability of Hs683 glioma cells subjected to ionizing irradiation or temozolomide *in vitro* \[[@b13-medscimonit-24-2259]\]. Prdx1 averts ROS-induced senescence in breast cancer by stimulating MKP-5 activity \[[@b14-medscimonit-24-2259]\].

Many studies have shown that Prdx1 is overexpressed in ESCC cells compared to non-cancerous esophageal epithelial cells \[[@b15-medscimonit-24-2259],[@b16-medscimonit-24-2259]\]. In the same way, elevated Prdx1 tends to facilitate tumorigenesis by controlling mTORp70S6K pathway activity in ESCC \[[@b16-medscimonit-24-2259]\]. Also, Prdx1 is upregulated in NSCLC tissue interstitial fluid, and a high degree of Prdx1 expression may be associated with lymph node metastasis and tumor differentiation, which suggests that Prdx1 is a neoplastic progression marker \[[@b17-medscimonit-24-2259]\]. Elevated Prdx1 advances prostate tumor vasculature and exhibits upregulation of antigenic proteins, including VEGF, in the tumor region. On the other hand, suppressing of Prdx1 in prostate cancer cell lines tends to reduce formation of tumor vascular, and brings about VEGF downregulation \[[@b18-medscimonit-24-2259],[@b19-medscimonit-24-2259]\]. Our study is the first to demonstrate a link between high Prdx1 expression and poor prognosis in GC patients after surgery. Our work demonstrates that Prdx1 plays a role in advancement of GC. Nonetheless, further studies are needed to advance understanding of the molecular mechanism and the latent roles of Prdx1 in GC.

EMT is a central driver of epithelial-derived tumor malignancies. It has been shown to trigger the dissociation of carcinoma cells from primary carcinomas, which subsequently migrate and disseminate to distant sites \[[@b20-medscimonit-24-2259],[@b21-medscimonit-24-2259]\]. There has also been a number of confirmed associations between EMT activation and improved tumorigenesis in different human cancer cell lines \[[@b22-medscimonit-24-2259]\]. As such, carcinoma cells with activated EMT program might uphold its continual expression in a cell-independent way by means of self-reinforcing positive-feedback loops \[[@b23-medscimonit-24-2259]\]. For instance, for breast cancer, achievement of mesenchymal facets is positively correlated with more destructive subtypes of this disease and tumor development \[[@b24-medscimonit-24-2259]--[@b26-medscimonit-24-2259]\]. Different studies have also demonstrated that EMT participates in the generation, development, and metastasis of GC \[[@b27-medscimonit-24-2259]--[@b29-medscimonit-24-2259]\]. Emerging evidence shows that human Prdx1 modulates epithelial-mesenchymal transition through its peroxides activity in A549 lung adenocarcinoma cells \[[@b30-medscimonit-24-2259]\]. The present study illustrates the association between EMT and Prdx1 in GC and shows high expression of Prdx1 (67.2%) but low expression of E-Ca (56.1%) in gastric cancer tissues. We established a substantial relationship between Prdx1 and EMT based on the expression of Prdx1 and E-Ca. High expression of Prdx1 was found to be related to poor differentiation, deeper invasion, and advanced TNM stage of GC, along with significant association of low expression of E-Ca. High expression of Prdx1 or low expression of E-Ca suggests a poor prognosis. *In vitro* experimentation validated that Prdx1 promotes the invasion and metastasis activity of GC cell through the mechanism of EMT. Taken all together, our findings suggest a connection between Prdx1 and EMT in GC tissues.

One of the main limitations of our single-center study is the relatively small sample size. In addition, the retrospective design may have contributed to selection bias. Accordingly, a prospective study with a larger cohort of patients is needed to confirm our findings. Also, more studies are needed to determine the mechanism by which EMT and Prdx1 interact with each other.

Conclusions
===========

Our study has demonstrated that upregulation of Prdx1 is correlated with progression of tumors in GC. We carried out primary research to explore the relationship between EMT and Prdx1. Further studies on the biological significance of elevated expression of Prdx1 in GC are needed and will help determine if the expression level of Prdx1 can be used as a prognostic biomarker for GC.
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![Expression of Prdx1 and E-Ca protein in GC tissue. Immunohistochemistry staining revealed Prdx1 and E-Ca high expression (**A, D**) and low expression (**B, C**).](medscimonit-24-2259-g001){#f1-medscimonit-24-2259}

![The levels of Prdx1 mRNA in 60 paired GC and corresponding adjacent normal tissues were measured by RT-PCR.](medscimonit-24-2259-g002){#f2-medscimonit-24-2259}

![The levels of Prdx1 protein in 4 paired GC and corresponding adjacent normal tissues were measured by Western blotting.](medscimonit-24-2259-g003){#f3-medscimonit-24-2259}

![Kaplan-Meier survival curves for OS and DFS according to the high and low expression of Prdx1 from 189 patients with GC. (**A**) Patients with high expression of Prdx1 showed a poor OS (P\<0.001). (**B**) Patients with high expression of Prdx1 had a poor DFS (P\<0.001).](medscimonit-24-2259-g004){#f4-medscimonit-24-2259}

![Kaplan-Meier survival curves for OS according to the high and low expression of E-Ca from 189 patients with GC. (**A**) Patients with high expression of E-Ca showed a favorable OS (P\<0.001). (**B**) Patients with high expression of E-Ca had a favorable DFS (P\<0.001).](medscimonit-24-2259-g005){#f5-medscimonit-24-2259}

![Transwell experiment revealed that the invasion and metastasis ability of GC cell lines was attenuated by inhibiting Prdx1 expression.](medscimonit-24-2259-g006){#f6-medscimonit-24-2259}

![EMT-related markers expression in the GC cells transfected with si-Prdx1 or controls were measured by Western blotting.](medscimonit-24-2259-g007){#f7-medscimonit-24-2259}

###### 

Expression correlation of Prdx 1 with E-ca in gastric cancer tissues.

  Group             Prdx 1 expression   *r*   *P*-value   
  ----------------- ------------------- ----- ----------- -------
  E-Ca expression                             −0.154      0.035
   High             49                  34                
   Low              78                  28                

###### 

Relationships between Prdx 1 and E-Ca protein expressions (immunohistochemical staining) in gastric cancer tissues and various clinicopathological variables.

  Variables                    Total   Prdx 1 expression   E-Ca expression                                         
  ---------------------------- ------- ------------------- ----------------- -------- --------- ---- ---- -------- ---------
  Gender                                                                                                           
   Male                        134     42                  92                0.446    0.504     77   57   0.355    0.551
   Female                      55      20                  35                                   29   26            
  Age at surgery (yeas)                                                                                            
   ≤60                         90      34                  56                1.928    0.165     48   42   0.528    0.467
   \>60                        99      28                  71                                   58   41            
  Size of primary tumor (cm)                                                                                       
   ≤5                          95      31                  64                0.003    0.959     51   44   0.447    0.504
   \>5                         94      31                  63                                   55   39            
  Borrmann type                                                                                                    
   I+II type                   63      21                  42                0.012    0.913     32   31   1.074    0.300
   III+IV type                 126     41                  85                                   74   52            
  Degree of differentiation                                                                                        
   Well/moderate               86      37                  49                7.476    0.006\*   41   45   4.532    0.033\*
   Poor and not                103     25                  78                                   65   38            
  Histological type                                                                                                
   Adenocarcinoma              160     54                  106               0.423    0.515     92   68   0.848    0.357
   Others                      29      8                   21                                   14   15            
  Depth of invasion                                                                                                
   T1                          8       5                   3                 15.592   0.001\*   1    7    18.040   0.000\*
   T2                          22      14                  8                                    6    16            
   T3                          59      18                  41                                   41   18            
   T4                          100     25                  75                                   58   42            
  Lymph node metastasis                                                                                            
   N0                          43      19                  24                9.060    0.029\*   22   21   0.753    0.861
   N1                          47      20                  27                                   26   21            
   N2                          54      14                  40                                   31   23            
   N3                          45      9                   36                                   27   18            
  TNM stage                                                                                                        
   I                           13      9                   4                 19.911   0.000\*   3    10   8.502    0.037\*
   II                          63      29                  34                                   34   29            
   III                         100     22                  78                                   59   41            
   IV                          13      2                   11                                   10   3             

###### 

Univariate analysis of the correlation between clinicopathological parameters and overall survival time of patients with gastric cancer.

  Variable                     Mean survival time (m)   95% CI           Log-rank test   *P*
  ---------------------------- ------------------------ ---------------- --------------- -------
  Gender                                                                                 
   Male                        45.176                   40.777--49.575   0.185           0.667
   Female                      43.625                   36.506--50.743                   
  Age at surgery(yeas)                                                                   
   ≤60                         46.517                   41.149--51.886   0.728           0.394
   \>60                        43.265                   38.076--48.455                   
  Size of primary tumor (cm)                                                             
   ≤5                          43.930                   38.878--48.983   0.269           0.604
   \>5                         45.856                   40.346--51.367                   
  Borrmann type                                                                          
   I+II type                   46.424                   39.813--53.036   0.383           0.536
   III+IV type                 43.865                   39.332--48.398                   
  Degree of differentiation                                                              
   Well/moderate               50.851                   45.619--56.084   9.127           0.003
   Poor and not                39.423                   34.335--44.511                   
  Histological type                                                                      
   Adenocarcinoma              43.538                   39.499--47.577   2.325           0.127
   Others                      50.305                   41.127--59.483                   
  Depth of invasion                                                                      
   T1                          71.000                   69.303--72.697   26.470          0.000
   T2                          62.943                   54.835--71.051                   
   T3                          44.625                   37.253--51.997                   
   T4                          42.050                   36.672--47.428                   
  Lymph node metastasis                                                                  
   N0                          53.041                   45.855--60.226   19.629          0.000
   N1                          53.249                   46.494--60.005                   
   N2                          40.014                   33.478--46.550                   
   N3                          33.437                   25.676--41.198                   
  TNM stage                                                                              
   I                           71.200                   69.798--72.602   58.227          0.000
   II                          49.310                   43.488--55.132                   
   III                         41.753                   36.547--46.959                   
   IV                          14.115                   10.384--17.846                   
  Prdx 1 expression                                                                      
   Low                         58.502                   53.447--63.556   20.998          0.000
   High                        38.207                   33.658--42.756                   
  E-Ca expression                                                                        
   Low                         36.536                   31.926--41.146   19.155          0.000
   High                        54.224                   48.989--59.458                   

###### 

Multivariate analysis of the correlation between clinicopathological parameters and overall survival time of patients with gastric cancer.

  Covariates                                        HR      95% CI for HR   P
  ------------------------------------------------- ------- --------------- -------
  Gender (Male *vs.* Female)                        0.913   0.579--1.439    0.694
  Age (≥60 *vs.* \<60 cm)                           1.080   0.718--1.624    0.713
  Tumor size (≥5 *vs.* \<5 cm)                      0.839   0.548--1.284    0.418
  Borrmann type (type I, II *vs.* III, IV)          1.075   0.691--1.672    0.748
  Degree of differentiation                         0.728   0.475--1.114    0.144
  Histological type                                 1.759   0.920--3.363    0.088
  Depth of invasion (T3, T4 *vs.* T1, T2)           0.236   0.088--0.638    0.004
  Lymph node metastasis                             0.333   0.156--0.711    0.005
  TNM stage (stage I *vs.* II *vs.* III *vs.* IV)   1.911   0.851--4.292    0.117
  Prdx 1 expression (low *vs.* high)                0.411   0.242--0.700    0.001
  E-Ca expression (low *vs.* high)                  1.698   1.082--2.664    0.021

###### 

Univariate analysis of the correlation between clinicopathological parameters and disease-free survival time of patients with gastric cancer.

  Variable                     Mean survival time (m)   95% CI           Log-rank test   *P*
  ---------------------------- ------------------------ ---------------- --------------- -------
  Gender                                                                                 
   Male                        42.675                   37.864--47.487   0.026           0.873
   Female                      41.668                   34.077--49.260                   
  Age at surgery (yeas)                                                                  
   ≤60                         44.413                   38.562--50.265   0.624           0.430
   \>60                        40.824                   35.209--46.439                   
  Size of primary tumor (cm)                                                             
   ≤5                          41.283                   35.785--46.781   0.274           0.601
   \>5                         43.781                   37.813--49.748                   
  Borrmann type                                                                          
   I+II type                   44.407                   37.282--51.531   0.469           0.493
   III+IV type                 41.486                   36.547--46.424                   
  Degree of differentiation                                                              
   Well/moderate               48.799                   43.077--54.521   7.959           0.005
   Poor and not                37.144                   31.616--42.671                   
  Histological type                                                                      
   Adenocarcinoma              41.130                   36.762--45.499   1.961           0.161
   Others                      47.854                   37.543--58.165                   
  Depth of invasion                                                                      
   T1                          69.250                   64.582--73.918   28.117          0.000
   T2                          62.579                   54.201--70.958                   
   T3                          42.457                   34.491--50.423                   
   T4                          39.473                   33.659--45.287                   
  Lymph node metastasis                                                                  
   N0                          50.574                   42.663--58.485   18.060          0.000
   N1                          51.080                   43.649--58.510                   
   N2                          37.015                   29.857--44.173                   
   N3                          31.325                   22.864--39.787                   
  TNM stage                                                                              
   I                           70.429                   67.577--73.280   45.520          0.000
   II                          46.928                   40.568--53.289                   
   III                         39.531                   33.837--45.225                   
   IV                          10.846                   6.640--15.052                    
  Prdx 1 expression                                                                      
   Low                         56.937                   51.396--62.477   21.481          0.000
   High                        35.519                   30.553--40.484                   
  E-Ca expression                                                                        
   Low                         33.797                   28.696--38.898   18.717          0.000
   High                        52.490                   46.853--58.127                   

###### 

Multivariate analysis of the correlation between clinicopathological parameters and disease-free survival time of patients with gastric cancer.

  Covariates                                        HR      95% CI for HR     P
  ------------------------------------------------- ------- ----------------- -------
  Gender (Male *vs.* Female)                        1.014   0\. 645--1.595    0.952
  Age (≥60 *vs.* \<60 cm)                           1.092   0\. 726--1. 642   0.673
  Tumor size (≥5 *vs.* \<5 cm)                      0.871   0\. 571--1. 329   0.523
  Borrmann type (type I, II *vs.* III, IV)          1.030   0\. 664--1. 597   0.897
  Degree of differentiation                         0.761   0\. 497--1.165    0.208
  Histological type                                 1.483   0\. 879--3.218    0.116
  Depth of invasion (T3, T4 *vs.* T1, T2)           0.248   0.092--0.664      0.006
  Lymph node metastasis                             0.342   0.160--0.733      0.006
  TNM stage (stage I *vs.* II *vs.* III *vs.* IV)   1.846   0.825--4.131      0.135
  Prdx 1 expression (low *vs.* high)                0.405   0.239--0.687      0.001
  E-Ca expression (low *vs.* high)                  1.762   1.125--2.762      0.013
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